Basson M D, Ahlman H, Wangberg B, Modlin I M
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06510.
Am J Surg. 1993 Feb;165(2):288-97. doi: 10.1016/s0002-9610(05)80529-x.
Midgut carcinoid tumors derive from gut entoderm. These tumors may cause a complex of symptoms comprising the carcinoid syndrome by secreting a wide variety of bioactive agents in addition to serotonin. Such symptoms generally follow metastases to the liver but may also occur in primary ovarian or retroperitoneal tumors. After localization and biochemical characterization, the bioactivity of these tumors should be blocked by octreotide, sometimes in combination with other pharmacologic antagonists, so that primary resection may be performed safely. If curative resection is impossible, then a cytoreductive management scheme should be employed that includes surgical debulking and hepatic arterial embolization, followed by palliation with octreotide.
中肠类癌肿瘤起源于肠内胚层。这些肿瘤可能会引发一系列症状，除了血清素外，还会分泌多种生物活性物质，从而导致类癌综合征。此类症状通常在发生肝转移后出现，但也可能出现在原发性卵巢或腹膜后肿瘤中。在确定肿瘤位置并进行生化特征分析后，这些肿瘤的生物活性应通过奥曲肽来阻断，有时还需联合其他药理拮抗剂，以便能够安全地进行初次切除。如果无法进行根治性切除，则应采用减瘤治疗方案，包括手术减瘤和肝动脉栓塞，随后使用奥曲肽进行姑息治疗。
